Raltegravir Potassium Patent Expiration
Raltegravir Potassium is Used for treating HIV infection by inhibiting integrase. It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Raltegravir Potassium Patents
Given below is the list of patents protecting Raltegravir Potassium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Isentress Hd | US10772888 | Solid pharmaceutical compositions containing an integrase inhibitor | Mar 30, 2032 | Msd Sub Merck |
| Isentress Hd |
US9649311 (Pediatric) | Solid pharmaceutical compositions containing an integrase inhibitor | Apr 21, 2031 | Msd Sub Merck |
| Isentress Hd | US9649311 | Solid pharmaceutical compositions containing an integrase inhibitor | Oct 21, 2030 | Msd Sub Merck |
| Isentress | US8771733 | Pharmaceutical composition containing an anti-nucleating agent | Jun 02, 2030 | Msd Sub Merck |
| Isentress Hd | US8771733 | Pharmaceutical composition containing an anti-nucleating agent | Jun 02, 2030 | Msd Sub Merck |
| Isentress |
US7754731 (Pediatric) | Potassium salt of an HIV integrase inhibitor | Sep 11, 2029 | Msd Sub Merck |
| Isentress Hd |
US7754731 (Pediatric) | Potassium salt of an HIV integrase inhibitor | Sep 11, 2029 | Msd Sub Merck |
| Isentress | US7754731 | Potassium salt of an HIV integrase inhibitor | Mar 11, 2029 | Msd Sub Merck |
| Isentress Hd | US7754731 | Potassium salt of an HIV integrase inhibitor | Mar 11, 2029 | Msd Sub Merck |
| Isentress | US8852632 | Pharmaceutical formulation containing a release rate controlling composition | Jan 28, 2028 | Msd Sub Merck |
| Isentress |
US7169780 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 03, 2024
(Expired) | Msd Sub Merck |
| Isentress Hd |
US7169780 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 03, 2024
(Expired) | Msd Sub Merck |
| Isentress | US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 03, 2023
(Expired) | Msd Sub Merck |
| Isentress | US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 03, 2023
(Expired) | Msd Sub Merck |
| Isentress Hd | US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 03, 2023
(Expired) | Msd Sub Merck |
| Isentress |
US7217713 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 21, 2023
(Expired) | Msd Sub Merck |
| Isentress |
US7435734 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 21, 2023
(Expired) | Msd Sub Merck |
| Isentress Hd |
US7217713 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 21, 2023
(Expired) | Msd Sub Merck |
| Isentress Hd |
US7435734 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 21, 2023
(Expired) | Msd Sub Merck |
| Isentress | US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 21, 2022
(Expired) | Msd Sub Merck |
| Isentress | US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 21, 2022
(Expired) | Msd Sub Merck |
| Isentress Hd | US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 21, 2022
(Expired) | Msd Sub Merck |
| Isentress Hd | US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 21, 2022
(Expired) | Msd Sub Merck |
Raltegravir Potassium's Family Patents
Explore Our Curated Drug Screens
Raltegravir Potassium Generic API Manufacturers
Only one generic application has been filed for Raltegravir Potassium.
Given below is the list of companies who have filed for Raltegravir Potassium generic, along with the locations of their manufacturing plants worldwide.
1. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 1 generic for Raltegravir Potassium. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Dec 19, 2024 |